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Abstract
The potential of early neurological inaccurate assessment of severity in patients 
with traumatic brain injury (TBI) has been highlighted; in some cases, for example, 
the severity of the injury is overestimated or underestimated. These findings have 
led to the search of biomarkers associated with early brain injury. Research in this 
field has exponentially increased over the past 20 years, with most publications on 
the subject in the last 10 years, whose results range from promising findings to other 
sometimes inconclusive one. An ideal biomarker should be able to demonstrate 
high sensitivity and specificity for brain injury, among other aspects. Literature has 
shown that there is not a single biomarker that predicts the patient’s clinical decline 
with high sensitivity and specificity. Instead, it is required to use a panel of markers 
that reflect different aspects of head trauma. This chapter gives a review of the most 
promising biomarkers studied as predictors of severity of TBI, with a special focus 
on their nature, location, basal concentrations, and methods by which they can be 
quantified in blood samples.
Keywords: acute brain injury, biomarkers, blood-brain barrier, prognosis,  
Glasgow Coma Scale
1. Introduction
Every year, 1.1 million Americans are treated in emergency rooms for traumatic 
brain injury (TBI): 235,000 are hospitalized for nonfatal TBI and 50,000 died. In 
Finland, a prospective study found that 3.8% of the population had experienced 
at least one hospitalization due to traumatic brain injury before 35 years of age. 
Similarly, another study in New Zealand found that at 25 years of age, 31.6% of 
the population had experienced at least one TBI that required medical attention 
(hospitalization, emergency department, or doctor’s office). It is estimated that 
43.3% of Americans have residual disability 1 year after the damage. The most 
recent estimate of the prevalence of the US civilian residents living with disability 
after hospitalization with TBI is 3.2 million [1].
TBI is assessed and classified clinically according to the Glasgow Coma Scale 
(GCS) [2] and by imaging: axial computed tomography (CT) and magnetic reso-
nance imaging (MRI). However, the use of GCS as a diagnostic tool is subject to 
important limitations, and it is difficult to assess the eye opening in patients with 
serious lesions on the face; likewise, the verbal response cannot be correctly esti-
mated in individuals who are under the influence of psychoactive drugs  
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and/or alcohol, and in those who are intubated or sedated will have limited linguis-
tic capacities [3]. Given that the severity of the neurological injury may be under-
estimated in some cases and overestimated in others, attention has been focused on 
early assessment strategies in patients with TBI and their inaccuracy in special and 
frequent circumstances [4].
In view of the high rate of intubation and difficulties in the proper evaluation of 
the eye opening, Stocchetti et al. concluded that motor GCS score was more impor-
tant than eye opening or verbal responses to predict the severity of the neurological 
injury. Other recent research has provided evidence that the use of sedative drugs 
avoids the accurate assessment of GCS during the first 24 h [5].
Other challenges for diagnosis are presented by the progressive nature of some 
brain injuries, which can lead to further neurological deterioration. In addition, 
neurological responses after TBI may vary over time for reasons unrelated to the 
injury. For example, trauma is frequently associated with alcohol and drug intoxi-
cation [6]. These factors together place the GCS in a position full of limitations 
that diminish its reliability as a highly sensitive test in specific and not infrequent 
circumstances such as those already mentioned.
On the other hand, neuroimaging techniques are used to provide objective 
information about the injury and its location [7] and are not influenced by the 
aforementioned confounding factors. However, the CT scan has a low sensitivity for 
diffuse brain injury, when the TBI is mild [8] and the availability and usefulness of 
MRI in the acute stage is limited. These facts, among others, have led to the search 
for alternative methods to assess the damage, being of special interest, the search 
for biomarkers, which are more reliable indicators of neuronal injury, due to its 
molecular context and its early expression.
Research in this field has increased exponentially in the last 20 years, with most 
publications on the subject in the last 10 years. Most markers are associated with 
cell damage. Table 1 presents a summary of the TBI biomarkers most studied to 
date, including information about their nature, tissue location, molecular weight, 
half-life, basal levels, and physiopathological significance.
The main physiopathological mechanisms reflected by the glial or neuronal 
biomarkers are the disruption of the blood-brain barrier (BBBD) and neuronal 
injury, respectively. Taking into account this basis, it would be advantageous to have 
a panel of complementary biomarkers that show different temporal profiles and 
that reflect different physiopathological conditions subsequent to TBI. In a parallel 
manner, Papa et al. [9] propose that an ideal biomarker should have the following 
characteristics:
1. demonstrate high sensitivity and specificity for brain injury;
2. stratify the patients according to the severity of the injury;
3. have rapid appearance in the accessible biological liquid;
4. provide information about injury mechanisms;
5. have biokinetic properties;
6. monitor the progress of the disease and the response to the treatment;
7. predict the functional result; and

































Biomarker Location Molecular mass [KDa] Nature Half life Basal concentrations Significance
UCH-L1 Neuronal 20 [41]
24 [42]
Ubiquitination enzyme 20 minutes [43] 0.12 ng/mL [44] Neuronal injury









Neuronal 280 [41] Cytoskeleton component 
protein
2.9 h [48] — Apoptosis
SBDP 120 [41] 1.5 days [49]
145 [41] 1 day [49]
150 [41] 1 day [49]
S-100B Glial (astrocytes) 21 [50] Calcium binding protein 97 minutes [47]
112 minutes [43]
0.328–0.01 pg/mL [11] BBBD
MBP Glial (oligodendrocytes and 
Schwann cells)
18.5 [50] Myelin sheath component 
protein
12 h [43] <0.3 ng/mL [50] White matter injury
GFAP Glial (astrocytes) 40–53 [30] Cytoskeleton component 
protein
— <0.03 ng/mL [30] BBBD and neuronal 
injury
Table 1. 
Main biomarkers in TBI and their properties.
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In this chapter, we present a compendium of the most studied biomarkers in the 
TBI, its possible applications, and the current techniques for its detection.
2. Most studied biomarkers in TBI
As explained in previous paragraphs, there is no single biomarker that is suffi-
ciently sensitive and specific to study the physiopathological mechanisms that derive 
from head trauma. Next, we will mention some of the most studied biomarkers given 
its rapid elevation after trauma and its relationship with the mechanism of injury. One 
of the most studied biomarkers is the Ca binder protein S-100β, a glial protein at the 
astrocyte level that is related to alterations in the blood-brain barrier [10]. Its rapid 
elevation and its considerable concentration release in the serum facilitate the study of 
the protein and its correlation with the severity of the injury. Due to the type of cells 
found in the central nervous system, it is necessary to study biomarkers that allow 
us to demonstrate not only glial injury but also neuronal. One of the most studied 
biomarkers in this sense is the C-terminal hydrolase of ubiquitin-L1, which is a highly 
specific cytoplasmic neuronal enzyme [11, 12]. Finally, we will delve into glial fibril-
lary acidic protein (GFAP), which is also a glial protein and is part of the cytoskeleton 
of astrocytes and is also related to the disruption of the blood-brain barrier [11, 13].
2.1 The Ca binder protein S-100β
S-100 β is a central nervous system (CNS) protein found predominantly in astro-
cytes and is the most studied peripheral biomarker of BBBD. This calcium binding 
protein (CBP) S-100β increases initially after the accident and then decreases 
rapidly after the traumatic injuries. In cell models, their release has been demon-
strated from the first 15 seconds after the trauma. In humans, the earliest that has 
been detected is 30 minutes posttrauma. The approximate half-life of this protein is 
97 minutes [10], the peak occurs on day 0, and the concentrations decrease toward 
the sixth day in both CSF and serum.
Goyal et al. [14] reported basal levels of S-100β in healthy CSF controls of 
0.0754–0.0034 ng/mL and in serum of 0.328–0.101 pg/mL. This protein has been 
studied extensively in mild TBI (mTBI), so that high levels in serum are associated 
with an increase in the incidence of post-concussion syndrome [15] and neurologi-
cal dysfunction. There are also several studies that have reported a correlation 
between serum levels of S-100β and the presence of pathological findings in 
cerebral magnetic resonance imaging (MRI), as well as abnormalities in neuropsy-
chological exploration after mTBI [16].
Most studies show that the S-100β measurement can distinguish injured patients 
from noninjured patients with an uncertain degree of utility in predicting mortal-
ity either acutely or at several points in time (Table 2) [17–19]. In general terms, 
S-100β is a sensitive but not specific predictor of CT abnormalities. Using low 
serum cut-off values, the sensitivity oscillates between 90 and 100% with a speci-
ficity between 4 and 65%.
Müller et al. [17] reported a sensitivity of 0.95 (95% CI 0.76–1.0) for S-100β 
measured within the first 12 h with a specificity of 31% (95% CI 0.25–0.38) relative 
to abnormal findings on skull CT scan in a study of 226 adult patients admitted to 
the hospital with a diagnosis of mild TBI (GCS 13–15). Biberthaler et al. [19] found 
similar results using a cut-off level of S-100β of 0.1 ng/mL, measured within the 
first 3 h posttrauma in 1309 patients with mTBI and correlating them to head CT 
findings. The sensitivity was 99% (95% CI 0.96–1.0), and the specificity was 30% 
(95% CI 0.29–0.31).
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The usefulness of S-100β as a marker does not seem to be affected by the 
concomitant consumption of alcohol. Mussack et al. conducted a study in which 
they included patients with mild TBI with demonstrated blood alcohol levels 
(mean = 182 mg/dL), and found that the sensitivity of S-100β in the first 3 h 
posttrauma was 100% (95% CI 0.83 a 1.0) and the specificity was 50% (95% CI 
0.41–0.59) [20].
On the other hand, Bazarian et al. studied 96 patients with TBI, GCS 13–15 who 
also presented trauma of extracranial localization, and found a sensitivity of 80% 
(95% CI 0.36–0.96) and a specificity of 40% (95% CI 0.01–0.09) for S-100β with a 
cut-off value of 0.08 ng/mL [21].
From the studies described above, it can be deduced that the sensitivity increases 
as the time elapsed between the trauma and the sample taking (window) decreases, 
as well as an increase in specificity is observed when the cut-off value increases. 
In contrast, the limitations of the use of S-100β as a marker are due to the marked 
decrease in sensitivity and specificity in the context of the polytraumatized patient, 
since the presence of concomitant extracranial trauma also causes the release 
and plasma elevation of this protein. The presence of S-100β has been reported 
in tissues other than the nervous one, mainly in adipose tissue [22]. From this 
observation, a negative effect on the specificity of this marker is expected, due to 
the increase that would occur in the context of extracranial lesions, as occurs in the 
polytraumatized patient.
Pham et al. [22] characterized the tissue specificity of S-100β and evaluated the 
extracranial sources of this marker and how they affect serum levels of this marker. 
For this purpose, they performed the extraction of proteins from nine different 
human tissues (liver, bladder, kidney, colon, lung, muscle, pancreas, adipose tissue, 
brain, tonsils, stomach, and skin) and their subsequent analysis through ELISA 
Reference Detection method Sample Findings
Goyal et al. 
[14]
ELISA CSF and 
serum
Increase in CSF and serum first 6 days 
post-trauma
Correlation between serum and CSF levels 
decreased over time
Level in CSF is a potential predictor of GOS 
and DRS





system [AB DiaSorin, 
Bromma, Sweden]
Serum Significantly elevated in intracranial injury
It cannot replace the clinical examination or 
the use of CT in mTBI
It can serve as support for the selection of 
patients for TC
S: 90–100%, E: 4–65%
Biberthaler 
et al [19]
Elecsys S100 [Roche 
Diagnostics, Mannheim, 
Germany]
Serum Increase was related to findings in the CT 
scan
S: 99%, E: 30%
Biberthaler 
et al [52]
Long term and Rapid test Serum Concentrations were significantly correlated 
using the two measurement techniques; 
cut-off value calculated: 0.18 ng/mL.
S: 100%, E: 46%
Bazarian, 
et al [21]
ELISA Serum S: 80%, E: 40%
Table 2. 
Summary of the evidence reported in the literature on biomarkers in S-100B.
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and Western blot in 200 subjects receiving chemotherapy for the management of 
CNS lymphomas. A dose of mannitol (1.4M) was administered intra-arterially in 
the carotid or vertebral artery, subsequently confirming the presence of BBBD by a 
head CT performed immediately after chemotherapy.
The results presented in that study showed that extracranial sources of S-100β 
do not affect serum levels. Therefore, the diagnostic value and the negative predic-
tive value of S-100β are not compromised in the context of patients with neurologi-
cal diseases, but without traumatic lesions, whether cerebral or extracranial.
Goyal et al. [14] also evaluated S-100β as a prognostic biomarker in adult 
subjects with severe TBI (sTBI) by comparing the results with the S-100β temporal 
profiles in both CSF (n = 138 subjects) and serum (n = 80 subjects) for 6 days. The 
variables used to evaluate the extracerebral sources of S-100β in serum were: long 
bone fracture, Injury Severity Score (ISS), and isolated skull trauma. After TBI, 
levels of S-100β in CSF and serum were increased compared to healthy controls 
during the first 6 days after TBI (p ≤ 0.005 and p ≤ 0.031). Although levels in CSF 
and serum had a high correlation at the early post-TCE time points, this associa-
tion decreased with time. The bivariate analysis showed that subjects who had 
temporary CSF profiles with higher concentrations of S-100B had higher acute 
mortality (p < 0.001) and worse Glasgow Outcome Scale (GOS; p = 0.002) and 
disability scores (DRS) (p = 0.039) 6 months after the injury. Temporary profiles 
in serum were associated with acute mortality (p = 0.015), possibly as a result 
of the extracerebral sources of S-100β in the serum, represented by high ISSs 
(p = 0.032).
Due to its temporal elevation profile, and the pathophysiological mechanisms 
that cause its release toward serum, S-100β constitutes an excellent candidate as an 
early biomarker of TBI, with the possible limitation in patients with concomitant 
trauma in other sites that leads to the serum elevation of S-100β from extracranial 
sources.
2.2 Ubiquitin C-terminal hydrolase-L1 (UCH-L1)
The C-terminal hydrolase of ubiquitin-L1 (ubiquitin C-terminal hydrolase-
L1, UCH-L1) is an E2 conjugation enzyme present in the cytoplasm of almost all 
neurons [13] and has previously been used as a neuronal histological marker due 
to its great abundance and specific expression in these cells [11]. Its location has 
also been shown in neurons of the peripheral nervous system, particularly in the 
neuromuscular junction [12], as well as in cells of the neuroendocrine system. In 
addition, the presence of UCH-L1 has been demonstrated in aortic endothelial cells 
and in smooth muscle and tumor cells [23]. This enzyme accomplishes the function 
of adding and removing ubiquitin from proteins in order to promote its degradation 
via the proteasome-dependent pathway [24].
UCH-L1 is one of the most recent biomarkers proposed for TBI, and for this 
reason, there are still limited data that demonstrate its usefulness (Table 3).
Three isoenzymes of UCH (UCH-L1, UCH-L2, and UCH-L3) have been identi-
fied, being UCH-L1, the only one present in high concentrations in the central ner-
vous system [24]. In a prospective case-control study with 66 patients, Papa et al. 
[24] obtained ventricular CSF samples for each patient after 6, 12, 24, 48, 72, 96, 
120, 144, and 168 h after TBI for the UCH-L1 detection by ELISA. The severity was 
determined by the Glasgow Scale (GCS) and CT findings. Mortality and neurologi-
cal sequelae were evaluated at 6 months. This study showed that patients with TBI 
had a significant elevation of CSF UCH-L1 levels at each point in time compared to 
controls, with total mean in TBI patients = 44.2 ng/mL (±7.9) vs. 2.7 ng/mL (±0.7) 
in controls (p < 0.001). Significantly elevated levels of UCH-L1 were found in 
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patients with a lower score in the GCS at 24 h, in those who had presented post-
trauma complications, in those who died within the first 6 weeks, and in those with 
severe sequelae at 6 months. These data suggest that this marker would be useful in 
determining severity in patients with TBI. Similar studies with larger samples are 
required to validate these findings.
Additional studies have confirmed the positive correlation between the concen-
trations of UCH-L1 at the CSF level and serum samples [25]. Similarly, Mondello 
Reference Detection method Sample Findings
Papa et al. 
[24]
ELISA CSF Increase at 6, 12, 24, 48, 72, 96, 120, 144, 
and 168 h post-trauma, X = 44.2 ng/mL 
(±7.9), versus controls X = 2.7 ng/mL (±0.7) 
(p < 0.001). Also elevated when it exists: lower 
GCS at 24 h, post-trauma complications, deaths 







Significant correlation between biokinetics 
and means of (UCH-L1) in CSF and serum in 
severe TBI (rs = 0.59, p < 0.001) (AUC, rs = 0.3, 
p = 0.027). Increased levels <24 h posttrauma, 
statistically significant in Cmax (0–24 h) in CSF 
and serum in those who died.
Mondello 
et al. [26]
Sandwich ELISA CSF 
and 
serum
It remains elevated up to 7 days after TBI, serum 
AUC and statistically significant CSF at all-time 
points up to 24 h (p < 0.001). Levels in <12 h 
in GCS 3–5 > GCS 6–8 (p = 0.07 and p = 0.02, 
Mann-Whitney test, respectively). Significantly 
higher and prolonged serum and CSF levels in 
non-survivors. A level of >5.22 ng/mL was a 
predictor of mortality (OR 4.8).
Papa et al. 
[11]
ELISA Serum Elevated in GCS 15 vs. controls without trauma 
(AUC 0.8) and controls with trauma. Higher 
elevation in GCS 15 plus TAC or neurosurgical 
intervention requirement. It provides evidence 





Serum Complements brain MRI in the detection of 
injury. Significantly elevated levels in patients in 




Sandwich ELISA Serum Measurement <24 h posttrauma distinguished 
presence and absence of intracranial lesions 
(AUC of 0.713). No correlation between 
levels in mild TCE and recovery at 6 months. 
Significant increase in levels in moderate/
severe TCE compared with mild TBI. Good 
sensitivity to discriminate between TCE and 
controls (AUC 0.87). Combination with GFAP 
showed greater sensitivity and specificity for 
the diagnosis of TBI (AUC 0.94).
Puvenna 
et al. [15]
ELISA Serum There were no significant differences between 
the levels of negative controls and TCE <6 h 
posttrauma, independent of the CT.
The levels were high after each game but 
without correlation with the number of hits 
received.
Table 3. 
Summary of the evidence reported in the literature on UCH-L1.
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et al. [26] conducted a case-control study with 95 patients with severe TBI in order 
to evaluate the CSF and serum concentrations of UCH-L1 by sandwich ELISA and 
its association with clinical results. The temporal profile of the marker in both CSF 
and serum was studied during the first 7 days following the trauma and compared 
with controls showing significantly higher levels compared to the controls through-
out the 7-day period, also confirming a high sensitivity and specificity for the 
diagnosis of TBI versus controls, with statistically significant serum AUC and CSF 
values at all-time points up to 24 h (p < 0.001).
The levels of UCH-L1 in the first 12 h in both CSF and serum in patients with 
GCS 3–5 were also significantly higher than in those with GCS 6–8. In addition, 
UCH-L1 levels in CSF and serum appeared to distinguish between patients with 
severe TBI survivors and nonsurvivors within the study, such that those who died 
had significantly higher CSF and serum UCHL1 levels, as well as greater perma-
nence of these levels over time. In this study, a serum level of UCH-L1 > 5.22 ng/mL 
was a predictor of mortality (OR 4.8).
Papa et al. [11] also analyzed UCH-L1 in serum taken in the first 4 h posttrauma 
in patients with mild (n = 86) and moderate (n = 10) TBI, as well as in controls 
with trauma and controls without trauma. For patients with a GCS of 15, serum 
UCH-L1 was significantly elevated compared to controls without trauma, with 
an AUC of 0.87, and was also compared with controls with trauma, and was even 
higher in those patients with GCS of 15 who also had positive findings on the CT 
scan or required some neurosurgical intervention, suggesting that UCH-L1 may 
be a potential marker of mild TBI. Additionally, 5% of patients with GCS of 15 
(4/77) required neurosurgical intervention, which was higher than the 1% found in 
patients with GCS 14–15 reported in the study by Jagoda et al., in which the samples 
were taken within the first 24 h posttrauma [10].
It is inferred from these data that the earlier it is detected posttrauma, the sensi-
tivity of this marker increases. In a smaller study (n = 9), serum UCHL1 (taken <6 h 
posttraumatic) was found to be significantly elevated in patients with mild TBI [27].
In another study focused on all levels of severity of TBI, serum UCH-1 measured 
before 24 h posttrauma could distinguish patients with intracranial lesions from 
those without intracranial lesions with an AUC = 0.713 [28]. However, there was no 
correlation between UCH-L1 levels in patients with mTBI and recovery at 6 months 
as measured by the GOSE scale. While there was a significant increase in UCH-L1 
levels in patients with moderate/severe TBI compared to mild TBI, patients with 
mild TBI were not compared with controls.
In a research carried out in a secondary school, Puvenna et al. [15] selected 15 
American football players; they obtained serum samples before and after each of 
two different games. They did not observe significant differences between the levels 
of UCH-L1 between the negative controls and the positive individuals for mild TBI 
within the first 6 h posttrauma, regardless of whether or not positive CT findings 
existed. In addition to this, there was no correlation between the serum levels of 
UCH-L1 and the number of impacts received. The levels of UCH-L1 and S-100β, 
markers of neuronal injury and BBBD, respectively, were both elevated after each 
game. However, only S-100β, unlike UCH-L1, was correlated with the number of 
hits received and the UCH-L1 elevation did not correlate with the S-100β incre-
ments. The authors suggest that elevated postgame UCH-L1 levels may be due to the 
release of this protein from the neuromuscular junction.
It can be concluded that there are very divergent data regarding the use of 
UCH-L1 as a serum biomarker of mild TBI. Some studies suggest that it is a 
promising marker, while others do not find a correlation with the lesion. Release 
from sources other than the central nervous system could contribute to elevated 
serum levels.
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2.3 The fibrillary acid glial protein (GFAP)
Glial fibrillary acidic protein (GFAP) is a protein derived from glial cells, which 
is a part of the intermediate filament of the cytoskeleton of astrocytes, where it is 
the most abundant protein. It is considered a specific marker of CNS diseases, and 
is also related to several neuronal processes’ harmful agents that compromise the 
integrity of the blood-brain barrier [29], and has been shown to be a potentially 
useful biomarker for predicting clinical outcomes in TBI. Its normal level in serum 
is <0.03 ng/mL [30], so any elevation thereof will indicate BBBD (Table 4).
Due to its great immunoreactivity, GAFP has been used as an indicator of brain 
injury in experimental models of mTCE [31]. The first successful measurement of 
GFAP in human blood was made in 1999 in 12 of 25 patients with severe TBI [32]. 
Using a weight drop model with mice [33] to evaluate two levels of mTBI, one with 
hemorrhage (complicated mTBI) and another without bleeding (uncomplicated 
mTBI), Yang et al. [34] found that serum GFAP was significantly elevated in both 
injury models at 90 minutes and 6 h after injury, but had returned to normal at 24 h.
In the study of Kou et al. [27], significantly elevated serum levels of GFAP in the 
first 24 h posttrauma in 9 mTBI patients was also reported; this elevation being even 
more significant in those with hemorrhagic lesions; however, the small size of the 
sample does not allow the conclusions to be validated.
In another study, Mondello et al. [35] evaluated whether the relationship 
between a neuronal marker (UCH-L1) and a glial marker (GFAP) correlates with 
the presence of different intracranial pathologies after brain trauma. They obtained 
serum samples from 59 patients with sTBI on admission to the hospital and mea-
sured levels of UCH-L1 and GFAP. The glial/neuronal ratio (GNR) was measured as 
the quotient between the concentrations of GFAP and UCH-L1. Logistic regression 
analysis identified variables associated with the type of injury. The increase in GNR 
was associated independently with the type of injury, but not with the age, gender, 
GCS, or trauma mechanism. This quotient was significantly higher in the patients 
who died, but it was not an independent predictor of mortality. The GNR had a 
median of 0.85 and correlated positively with age.
When evaluating the CT scan of the skull on admission, 29 patients presented 
a diffuse lesion and 30 localized lesions. The GNR was significantly higher in the 
group with focal lesions compared to the group with diffuse lesions. The receiver 
operating characteristic (ROC) analysis showed that the GNR discriminated 
between the two types of injury. GNR was more accurate when performed early 
than when it was done late (Table 4).
These data indicate that the GNR provides valuable information about the 
different types of injury, which is of great clinical utility. In addition, the GNR can 
help to identify the pathophysiological mechanisms subsequent to the different 
types of TBI. This is very useful when implementing therapeutic measures.
In an investigation carried out by Papa et al. [36], the capacity of the GFAP taken 
<4 h posttrauma was compared to predict intracranial lesions in the CT compared 
to S-100β. Although patients had GCS 9–15, only 3 of 209 patients had GCS <13 
and only 10% had intracranial lesions, both S-100β and GFAP were significantly 
elevated in all patients, and even more so in those with intracranial lesions. For 
those patients with GCS 14–15, the AUC for the identification of intracranial lesions 
was 0.82 for GFAP and 0.77 for S-100β.
In the presence of extracranial lesions and using a cut-off value of 0.067 ng/mL, 
GFAP was 100% sensitive and 55% specific in the prediction of intracranial lesions. 
With a cut-off value of 0.20 ng/mL, S-100β also had 100% sensitivity but only 5% 
specificity. This study concludes that GFAP exceeds S-100β in the identification of intra-
cranial lesions in mild and moderate TBI, even in the presence of extracranial lesions.
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In general, GFAP seems to increase in TBI and could represent a more sensitive 
marker than S-100β for the identification of intracranial lesions. However, for 
further validation, more studies are needed that focus specifically on mTBI (GCS 
13–15), which include appropriate controls and adequate statistical comparisons.
3. Discussions and conclusions
One of the main purposes of the search for potential biomarkers in the TBI is to 
predict the presence of pathological findings in head CT and brain MRI; however, 
the studies published in this regard are inconclusive, and the evidence favors the use 
of S-100β over other markers in mTBI, as a predictor of negative-CT.
For example, Posti et al. [37] showed that patients with orthopedic trauma 
had higher levels of GFAP at admission, than those with mTBI and negative-CT 
(p = 0.026), and did not show that UCH-L1 levels presented significant differences 
in both groups, performing measurements at different time points, which suggest 
that these markers are not useful for distinguishing patients with negative-CT mTBI 
from patients with orthopedic trauma, and that high levels of UCH-L1 or GFAP can 





Serum Significantly elevated in all cases of intracranial 
hemorrhage, with potential screening capacity. 




Sandwich ELISA Serum Evaluation of GNR (GFAP/UCH-L1): 
Median = 0.85, positive correlation with age 
(R = 0.45, p = 0.003). Greater in focalized 
lesions vs. diffuse lesion (1.77 vs. 0.48, 
respectively, p = 0.003). Different type of 
lesions (AUC = 0.72, p = 0.003). More precise 
early measurement (<12 h posttrauma) vs. 
late (AUC = 0.80, p = 0.002). Independent 
association with the type of injury, but not with 
the GCS. Independent predictor of mortality.
Papa et al. 
[36]
ELISA Serum S-100B and GFAP significantly elevated in all 
patients, especially in intracranial injuries. For 
GCS 14–15, AUC = 0.82 in identification of 
intracranial lesions for GFAP (0.77 for S-100B). 
With extracranial lesions and cut-off 0.067 ng/
mL, GFAP: S = 100% and E = 55% to predict 
intracranial lesions. GFAP outperforms S-100B 
in the identification of intracranial lesions in 




ELISA Serum GFAP-BDP significantly elevated in mild 
TCE vs. controls with or without trauma. 
AUC = 0.88 to identify brain injury in GCS 15. 
Higher levels in GCS 15 with positive CT.
Okonkwo 
et al. [55]
ELISA Serum GFAP-BDP <24 h posttrauma distinguished 
between mild and moderate/severe TBI (AUC 
of 0.87). Controls were not included, mild to 
moderate TCE was not compared, and most of 
the statistical analysis was made with all levels 
of severity at the time.
Table 4. 
Summary of the evidence reported in the literature on GFAP in TBI.
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lead to a false diagnosis of mTBI in polytraumatized patients, leading to the unnec-
essary use of neuroimaging.
On the other hand, the use of the S-100β marker has been recommended in the 
Scandinavian guidelines for the initial management of minimal, mild, and moder-
ate head injuries in adults [38] as an alternative to reduce the number of CT in the 
subgroup of mTBI with low risk of intracranial complications or surgical interven-
tions. More studies are needed that show the usefulness of S-100β as a predictor of 
neurodeterioration in moderate TBI.
The use of neuroimaging is necessary to improve the accuracy of biomarkers in 
the diagnosis and prognosis of patients who have suffered a TBI, with CT being the 
first option and the one with the most studies in relation to the release and correla-
tion of biomarkers. Some reviews report higher serum S-100β levels in more severe, 
focal lesions, compared to diffuse lesions using Marshall scale, and a strong correla-
tion between S100B increasing and the severity of the CT finding when using the 
sum of Rotterdam CT score and Stockholm CT score [54].
Olivecrona et al. reported how S-100β and neuronal specific enolase (NSE) 
levels correlate with CT findings using the aforementioned scales. Specifically, 
S-100β levels, but not to the NSE levels, correlates with Morris-Marshall score for 
the classification of traumatic subarachnoid hemorrhage (tSAH). This is probably 
associated with the physiopathological pathways described by each of these bio-
markers after a neurotrauma. Likewise, the volume of the parenchymal contusions 
is also associated with the S-100β levels. Furthermore, in mild TBI, initial low levels 
of S-100β can be used as a predictor of a stationary injury, suggesting that the CT 
classification does not evolve [55].
Diagnosis of severity and prognosis of CT findings cannot be performed by 
a single biomarker test. Instead, a combination of biomarkers of diverse origins 
and pathways displays a better performance. Thereby, the joint use of GFAP, heart 
fatty acid binding protein (H-FABP), S-100β, and IL-10 results in a more efficient 
diagnostic tool with a 46% specificity and 100% sensitivity for predicting CT 
injuries. This biomarker panel increases specificity by 14% compared to the best 
single biomarker [56].
The ALERT-TBI study, developed in 22 centers in USA and Europe, validated the 
ability of the combination of UCH-L1 and GFAP to predict CT injuries within 12 h of 
mTBI, resulting in a sensitivity of 97.6%, a negative predictive value (NPV) of 99.6%, 
and a specificity of 36.4%. Therefore, when indicating CT only in those patients with 
a positive GFAP and UCH-L1 test, the CT use could be reduced by approximately one-
third. The extent of these findings to patients with moderate TBI is uncertain [57].
The study of the available evidence on the different serum markers in TBI 
presented in this chapter allows us to conclude that, currently, there is not a single 
biomarker capable of predicting the clinical deterioration of patients with high 
sensitivity and specificity. However, the pathophysiological mechanisms of TBI 
suggest that instead, a panel of markers that reflect different aspects of traumatic 
injury should be available, including BBBD and neuronal injury.
The literature has shown that the joint use of S-100β and GFAP or UCH-L1 
would represent a valuable early prognostic and follow-up tool in TBI in addition to 
the GCS and the CT, thus guiding the decisions of initial management and aggres-
sive interventions.
Likewise, given that the kinetic profile of these markers is different, since it 
presents peaks of appearance earlier than others and different times of permanence 
in serum, its usefulness would also be correlated with different post-traumatic 
stages, so that S-100β and UCH-L1 are better early markers [24, 25], whereas GFAP 
is a better predictor of CT lesions and surgical interventions in the first 7 days post-
trauma in mild and moderate TBI [27].
Traumatic Brain Injury - Neurobiology, Diagnosis and Treatment
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In addition to the above, the literature also shows that these biomarkers are 
being measured with techniques that demand the use of complex equipment and 
procedures (such as ELISA) in which the use of labels is necessary [6, 39], display-
ing the need for the development of rapid and cost-effective techniques that allow 
the implementation of biomarkers in the clinical setting.
Acknowledgements
We thank Universidad del Norte and Colciencias for the financial support of the 
research project in which the development of this work is framed.
Conflict of interest
The authors declare no conflict of interest.
13
Neuronal and Glial Biomarkers Research for Traumatic Brain Injury
DOI: http://dx.doi.org/10.5772/intechopen.85555
References
[1] Corrigan J, Selassie A, Orman J. 
The epidemiology of traumatic brain 
injury. The Journal of Head Trauma 
Rehabilitation. 2010;2(2):72-80. DOI: 
10.1097/HTR.0b013e3181ccc8b4
[2] Matis G, Birbilis T. The Glasgow 
coma scale—A brief review past, 
present, future. Acta Neurologica 
Belgica. 2008;108(3):75-89
[3] Forastero P, Echevarria C, Barrera 
J. Traumatismos craneoencefálicos. 
Escalas de valoración para la medida 
de resultados en rehabilitación. 
Rehabilitación. 2002;36(6):408-417. 
DOI: 10.1016/S0048-7120(02)73314-8
[4] Stocchetti N et al. Inaccurate early 
assessment of neurological severity in 
head injury. Journal of Neurotrauma. 
2004;21(9):1131-1140. DOI: 10.1089/
neu.2004.21.1131
[5] Livingston B, Mackenzie S, MacKirdy 
F, Howie J. Should the presedation 
glasgow coma scale value be used when 
calculating acute physiology and chronic 
health evaluation scores for sedated 
patients? Critical Care Medicine. 
2000;28(2):389-394
[6] Mondello S, Muller U, Jeromin A, 
Streeter J, Hayes R, Wang K. Blood-
based diagnostics of traumatic brain 
injuries. Expert Review of Molecular 
Diagnostics. 2011;11(1):65-78. DOI: 
10.1586/erm.10.104
[7] Carney N et al. Guidelines for 
the management of severe traumatic 
brain injury, fourth edition. Journal of 
Neurotrauma. 2017;80(1):6-15. DOI: 
10.1227/NEU.0000000000001432
[8] Zhang J, Puvenna V, Janigro 
D. Biomarkers of traumatic brain injury 
and their relationship to pathology. 
In: Laskowitz D, Grant G, editors. 
Translational Research in Traumatic 
Brain Injury. Boca Raton, FL: CRC 
Press/Taylor and Francis Group; 2016. 
pp. 263-276. DOI: 10.1201/b18959-13
[9] Papa L et al. Use of biomarkers for 
diagnosis and management of traumatic 
brain injury patients. Expert Opinion on 
Medical Diagnostics. 2008;2(8):937-945. 
DOI: 10.1517/17530059.2.8.937
[10] Jagoda A et al. Clinical policy: 
Neuroimaging and decisionmaking in 
adult mild traumatic brain injury in 
the acute setting. Annals of Emergency 
Medicine. 2008;52(6):714-748. DOI: 
10.1016/j.annemergmed.2008.08.021
[11] Papa L et al. Serum levels of 
ubiquitin C-terminal hydrolase 
distinguish mild traumatic brain injury 
from trauma controls and are elevated 
in mild and moderate traumatic brain 
injury patients with intracranial lesions 
and neurosurgical intervention. Journal 
of Trauma and Acute Care Surgery. 
2012;72(5):1335-1344. DOI: 10.1097/
TA.0b013e3182491e3d
[12] Chen F, Sugiura Y, Myers K, Liu Y, 
Lin W. Ubiquitin carboxyl-terminal 
hydrolase L1 is required for maintaining 
the structure and function of the 
neuromuscular junction. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2010;107(4):1636-1641. DOI: 10.1073/
pnas.0911516107
[13] Bishop P, Rocca D, Henley J. 
Ubiquitin C-terminal hydrolase L1 
(UCH-L1): Structure , distribution 
and roles in brain function and 
dysfunction. The Biochemical Journal. 
2016;473(16):2453-2462. DOI: 10.1042/
BCJ20160082
[14] Goyal A et al. S100b as a prognostic 
biomarker in outcome prediction 
for patients with severe traumatic 
brain injury. Journal of Neurotrauma. 
2013;30(11):946-957. DOI: 10.1089/
neu.2012.2579
Traumatic Brain Injury - Neurobiology, Diagnosis and Treatment
14
[15] Puvenna V et al. Significance of 
ubiquitin carboxy terminal hydrolase 
L1 elevations in athletes after 
subconcussive head hits. PLoS One. 
2014;9(5):e96296. DOI: 10.1371/journal.
pone.0096296
[16] Adrian H et al. Biomarkers of 
traumatic brain injury: Temporal 
changes in body fluids. eNeuro. 
2016;3(6):ENEURO.0294-16.2016. DOI: 
10.1523/ENEURO.0294-16.2016
[17] Müller K et al. S100B serum level 
predicts computed tomography findings 
after minor head injury. The Journal of 
Trauma. 2007;62(6):1452-1456. DOI: 
10.1097/TA.0b013e318047bfaa
[18] Ingebrigtsen T et al. The clinical 
value of serum S-100 protein 
measurements in minor head injury: A 
Scandinavian multicentre study. Brain 
Injury. 2000;14(12):1047-1055
[19] Biberthaler P et al. Serum S100B 
concentration provides additional 
information for the indication 
of computed tomography in 
patients after minor head injury: A 
prospective multicenter study. Shock. 
2006;25(5):446-453. DOI: 10.1097/01.
shk.0000209534.61058.35
[20] Mussack T et al. Immediate S-100B 
and neuron-specific enolase plasma 
measurements for rapid evaluation 
of primary brain damage in alcohol-
intoxicated, minor head-injured 
patients. Shock. 2002;18(5):395-400
[21] Bazarian J, Beck C, Blyth B, Von 
Ahsen N, Hasselblatt M. Impact of 
creatine kinase correction on the 
predictive value of S-100B after mild 
traumatic brain injury. Restorative 
Neurology and Neuroscience. 
2010;24(3):163-172
[22] Pham et al. Extracranial sources of 
S100B do not affect serum levels. PLoS 
One. 2010;5(9):e12691. DOI: 10.1371/
journal.pone.0012691
[23] Campbell L, Thomas J, Lamps L, 
Smoller B, Folpe A. Protein gene 
product 9.5 (PGP 9.5) is not a specific 
marker of neural and nerve sheath 
tumors: An immunohistochemical study 
of 95 mesenchymal neoplasms. Modern 
Pathology. 2003;16(10):963-969. DOI: 
10.1097/01.MP.0000087088.88280.B0
[24] Papa et al. Ubiquitin C-terminal 
hydrolase is a novel biomarker in 
humans for severe traumatic brain 
injury. Critical Care Medicine. 
2010;38(1):138-144. DOI: 10.1097/
CCM.0b013e3181b788a
[25] Brophy G et al. Biokinetic analysis 
of ubiquitin C-terminal hydrolase-L1 
(UCH-L1) in severe traumatic brain 
injury patient biofluids. Journal of 
Neurotrauma. 2001;28(6):861-870. DOI: 
10.1089/neu.2010.156
[26] Mondello S et al. Clinical utility of 
serum levels of ubiquitin C-terminal 
hydrolase as a biomarker for severe 
traumatic brain injury. Neurosurgery. 
2012;70(3):666-675. DOI: 10.1227/
NEU.0b013e318236a809
[27] Kou Z et al. Combining biochemical 
and imaging markers to improve 
diagnosis and characterization of mild 
traumatic brain injury in the acute 
setting: Results from a pilot study. 
PLoS One. 2013;19(8):11, e80296. DOI: 
10.1371/journal.pone.0080296
[28] Diaz-Arrastia et al. Acute 
biomarkers of traumatic brain injury: 
Relationship between plasma levels of 
ubiquitin C-terminal hydrolase-L1 and 
glial fibrillary acidic protein. Journal of 
Neurotrauma. 2014;31(1):19-25. DOI: 
10.1089/neu.2013.3040
[29] Eng L, Ghirnikar R, Lee Y. Glial 
fibrillary acidic protein: GFAP-thirty-
one years (1969-2000). Neurochemical 
Research. 2000;25(9):1439-1451
[30] Ingebrigtsen T, Romner 
B. Biochemical serum markers of 
15
Neuronal and Glial Biomarkers Research for Traumatic Brain Injury
DOI: http://dx.doi.org/10.5772/intechopen.85555
traumatic brain injury. The Journal of 
Trauma. 2002;52(4):798-808
[31] Saatman K, Bolton A. Regional 
neurodegeneration and gliosis are 
amplified by mild traumatic brain injury 
repeated at {24-hour} intervals. Journal 
of Neuropathology and Experimental 
Neurology. 2014;73(10):933-947. DOI: 
10.1097/NEN.0000000000000115
[32] Missler U, Wiesmann M,  
Wittmann G, Magerkurth O, 
Hagenström H. Measurement of glial 
fibrillary acidic protein in human blood: 
Analytical method and preliminary 
clinical results. Clinical Chemistry. 
1999;45(1):138-141
[33] Albert-Weissenberger C, Sirén 
AL. Experimental traumatic brain 
injury. Experimental & Translational 
Stroke Medicine. 2010;2(1):16
[34] Yang S et al. A murine model 
of mild traumatic brain injury 
exhibiting cognitive and motor 
deficits. The Journal of Surgical 
Research. 2013;184(2):981-988. DOI: 
10.1186/2040-7378-2-16
[35] Mondello S et al. Glial neuronal 
ratio: A novel index for differentiating 
injury type in patients with severe 
traumatic brain injury. Journal of 
Neurotrauma. 2012;29(6):1096-1104. 
DOI: 10.1089/neu.2011.2092
[36] Papa L et al. GFAP out-performs 
S100beta in detecting traumatic 
intracranial lesions on computed 
tomography in trauma patients with 
mild traumatic brain injury and those 
with extracranial lesions. Journal of 
Neurotrauma. 2014;31(22):1815-1822. 
DOI: 10.1089/neu.2013.3245
[37] Posti JP et al. Glial fibrillary acidic 
protein and ubiquitin C-terminal 
hydrolase-L1 are not specific biomarkers 
for mild CT-negative traumatic brain 
injury. Journal of Neurotrauma. 2017. 
DOI: 10.1089/neu.2016.4442
[38] Undén L et al. Validation of the 
Scandinavian guidelines for initial 
management ofminimal, mild and 
moderate traumatic brain injury in 
adults. BMC Medicine. 2015;13:292. 
DOI: 10.1186/s12916-015-0533-y
[39] Strathmann FG et al. Blood-based 
biomarkers for traumatic brain injury: 
Evaluation of research approaches, 
available methods and potential 
utility from the clinician and clinical 
laboratory perspectives. Clinical 
Biochemistry. 2014;47(10-11):876-888. 
DOI: 10.1016/j.clinbiochem.2014.01.028
[40] Papa L, Brophy G, Welch R, 
Lewis L, Braga C, Tan C, et al. Time 
course and diagnostic accuracy of 
glial and neuronal blood biomarkers 
GFAP and UCH-L1 in a large cohort 
of trauma patients with and without 
mild traumatic brain injury. JAMA 
Neurology. 2016;73(5):551-560. DOI: 
10.1001/jamaneurol.2016.0039
[41] Kövesdi E, Lückl J, Bukovics P, 
Farkas O, Pál J, Czeiter E, et al. Update 
on protein biomarkers in traumatic 
brain injury with emphasis on clinical 
use in adults and pediatrics. Acta 
Neurochirurgica. 2010;152:1-17. DOI: 
10.1007/s00701-009-0463-6
[42] North S, Shriver-Lake L, 
Taitt C, Ligler F. Rapid analytical 
methods for on-site triage for 
traumatic brain injury. Annual 
Review of Analytical Chemistry. 
2012;5(1):35-56. DOI: 10.1146/
annurev-anchem-062011-143105
[43] Mondello S, Akinyi L, Buki A, 
Robicsek S, Gabrielli A, Tepas J, et al. 
NIH public access. 2013;70(3):666-675
[44] Benito I, Rodríguez J. 
Determinación radioinmunométrica 
de la enolasa neuronal específica en 
humor acuoso y suero, en pacientes con 
retinoblastoma. Revista Española de 
Medicina Nuclear e Imagen Molecular. 
2000;7:472-478
Traumatic Brain Injury - Neurobiology, Diagnosis and Treatment
16
[45] Test ID: NSESF. Neuron-Specific 
Enolase (NSE), Spinal Fluid [Internet]. 





[Accessed: 7 December 2018]
[46] Dash P, Zhao J, Hergenroeder G, 
Moore A. Biomarkers for the diagnosis, 
prognosis, and evaluation of treatment 
efficacy for traumatic brain injury. 
Neurotherapeutics. 2010;7(1):100-114. 
DOI: 10.1016/j.nurt.2009.10.019
[47] Wang K, Posmantur R, Nath R, 
McGinnis K, Whitton M, Talanian 
R, et al. Simultaneous degradation 
of alphaII and betaII-spectrin by 
caspase 3 (CPP32) in apoptotic cells. 
The Journal of Biological Chemistry. 
1998;273(35):22490-22497
[48] Brophy G, Pineda J, Papa L, 
Lewis S, Valadka A, Hannay H, et al. 
alphaII-Spectrin breakdown product 
cerebrospinal fluid exposure metrics 
suggest differences in cellular injury 
mechanisms after severe traumatic 
brain injury. Journal of Neurotrauma. 
2009;26(4):471-479. DOI: 10.1089/
neu.2008.0657
[49] Berger R, Hymel K, Gao W. The use 
of biomarkers after inflicted traumatic 
brain injury: Insight into Etiology, 
pathophysiology, and biochemistry. 
Clinical Pediatric Emergency Medicine. 
2006;7(3):186-193. DOI: 10.1016/j.
cpem.2006.06.001
[50] Biberthaler P, Mussack T, 
Wiedemann E, Kanz K-G, Mutschler 
W, Linsenmaier U, et al. Rapid 
identification of high-risk patients 
after minor head trauma (MHT) by 
assessment of S-100β: Ascertainment 
of a cut-off level. European Journal of 
Medical Research. 2002;7(4):164-170
[51] Brophy G, Mondello S, Papa L, 
Robicsek S, Gabrielli A, Tepas J, 
et al. Biokinetic analysis of ubiquitin 
C-terminal hydrolase-L1 (UCH-L1) in 
severe traumatic brain injury pa¬tient 
biofluids. Journal of Neurotrauma. 
2011;28(6):861-870. DOI: 10.1089/
neu.2010.1564
[52] Papa L, Lewis L, Falk J, Zhang SS, 
Giordano P, et al. Elevated levels of 
serum glial fibrillary acidic protein 
breakdown products in mild and 
moderate traumatic brain injury are 
associated with intracranial lesions 
and neurosurgical intervention. 
Annals of Emergency Medicine. 
2012;59:471-483. DOI: 10.1016/j.
annemergmed.2011.08.021
[53] Okonkwo D, Yue J, Puccio A, 
Panczykowski D, Inoue T, Mcmahon 
P, et al. GFAP-BDP as an acute 
diagnostic marker in traumatic brain 
injury: Results from the pros¬pective 
transforming research and clinical 
knowledge in traumatic brain injury 
study. Journal of Neurotrauma. 
2013;30(17):1490-1497. DOI: 10.1089/
neu.2013.2883
[54] Thelin E et al. A review of the 
clinical utility of serum S100B protein 
levels in the assessment of traumatic 
brain injury. Acta Neurochirurgica. 
2017;159(2):209-225. DOI: 10.1007/
s00701-016-3046-3
[55] Olivecrona Z et al. Association 
of ICP, CPP, CT findings and S-100B 
and NSE in severe traumatic head 
injury. Prognostic value of the 
biomarkers. Brain Injury. 2014:29. DOI: 
10.3109/02699052.2014.989403
[56] Lagerstedt L, Egea-Guerrero JJ, 
Bustamante A, Rodríguez-Rodríguez 
A, El Rahal A, Quintana-Diaz M, et al. 
Combining H-FABP and GFAP  
increases the capacity to differentiate 
between CT-positive and CT-negative 
patients with mild traumatic brain 
injury. PLoS One. 2018;13(7):e0200394. 
DOI: 10.1371/journal.pone.0200394
17
Neuronal and Glial Biomarkers Research for Traumatic Brain Injury
DOI: http://dx.doi.org/10.5772/intechopen.85555
[57] Bazarian JJ, Biberthaler P, Welch 
RD, Lewis LM, Barzo P, Bogner-Flatz 
V, et al. Serum GFAP and UCH-L1 for 
prediction of absence of intracranial 
injuries on head CT (ALERT-TBI): A 
multicentre observational study. Lancet 
Neurology. 2018;17(9):782-789. DOI: 
10.1016/S1474-4422(18)30231-X
